MediciNova falls 25.4% after fatty liver drug misses blood-fat significance

MN-001 lowered triglycerides in a 40-patient mid-stage trial, but the difference versus placebo was not statistically significant. HDL rose significantly; liver fat and weight reductions were not significant.